Partners seek EUA for COVID-19 booster jab in kids aged five to 11
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have submitted an application to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a 10µg booster dose of their COVID-19 jab for children aged five to 11 years of age.
The submission included data from the Phase II/III trial in children aged five through 11 years who received a booster dose approximately six months after the second dose of the Pfizer-BioNTech COVID-19 Vaccine 10µg two-dose primary series, which was authorized under EUA for this age group in October 2021.
Data from the study demonstrated a strong immune response in this age group following a booster dose of the vaccine. There were no new safety signals reported.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze